751 results on '"Finke, Christy"'
Search Results
2. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance
3. Spectrum of clonal hematopoiesis in VEXAS syndrome
4. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
5. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation
6. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
7. Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease
8. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
9. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information
10. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients
11. Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis
12. Mutations and thrombosis in essential thrombocythemia
13. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
14. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
15. Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants
16. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
17. A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone
18. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
19. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy
20. P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
21. Targeted deep sequencing in primary myelofibrosis
22. Targeted deep sequencing in polycythemia vera and essential thrombocythemia
23. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
24. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
25. Abstract 806: Enhancer deregulation inTET2-mutant clonal hematopoiesis is associated with increased COVID-19 severity and mortality
26. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients
27. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
28. Driver mutations and prognosis in primary myelofibrosis: Mayo‐Careggi MPN alliance study of 1,095 patients
29. A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
30. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
31. MPL-mutated essential thrombocythemia: a morphologic reappraisal
32. Genetic predictors of response to specific drugs in primary myelofibrosis
33. Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
34. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
35. Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
36. Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
37. Prevalence and Impact of Clonal Hematopoiesis in Therapy Related Myeloid Neoplasms Occurring in the Context of Low-Grade Follicular Lymphoma Treated with Radioisotope Therapy
38. Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance
39. DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways
40. U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations
41. Monocytopenia As an Adverse Prognosticator in Vexas Syndrome
42. Clonal Hematopoiesis in Vexas Syndrome
43. Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis
44. Therapy related‐chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML
45. Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance
46. One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
47. CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
48. Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
49. EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
50. Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.